Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to_____. Commission File Number: 001-41696 ACELYRIN, INC. (Exact name of registrant as specified in its charter) (Registrant's telepho ...

Exhibit 10.2 SEPARATION AGREEMENT AND MUTUAL RELEASE WHEREAS, Employee was employed by the Company as Chief People Officer; WHEREAS, Employee signed a Proprietary Information and Inventions Assignment Agreement with the Company (the "Confidentiality Agreement"); WHEREAS, the Company has granted to Employee the stock options listed on Exhibit A (the "Employee Options") and the restricted stock units listed on Exhibit A (the "Employee RSUs") pursuant to the terms and conditions of the Company's 2020 Stock Opt ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________ FORM 10-K ________________________________________ (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________ to __________________ Commission file number ...

Exhibit 99.1 ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent Highlights Reported positive Phase 1/2 proof-of-concept data for lonigutamab, first subcutaneous anti-IGF-1R to demonstrate clinical responses in thyroid eye disease patients Achieved primary endpoint with high statistical significance in global Phase 2b/3 clinical trial of izokibep in psoriatic arthritis with robust clinical responses also achieved for higher hurdle endpoints Announced differentiated long-term 32-week data from ...

Acelyrin Inc. (NASDAQ:SLRN) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ET Company Participants Tyler Marciniak - Vice President, Investor Relations, Communications, Corporate Operations Shao-Lee Lin - Founder, Chief Executive Officer and Director Gil Labrucherie - Chief Financial Officer Conference Call Participants Yasmeen Rahimi - Analyst, Piper Sandler Emily Bodnar - Analyst, H.C. Wainwright and Company Akash Tewari - Analyst, Jefferies Tyler Van Buren - TD Cowen Vikram Purohit - Morgan St ...

Financial Highlights - Cash, cash equivalents, and short-term marketable securities totaled $788.4 million as of September 30, 2023[7] - Research and development expenses were $74.6 million for the third quarter of 2023, compared to $12.5 million for the same period in 2022[8] - General and administrative expenses were $19.9 million for the third quarter of 2023, compared to $2.9 million for the same period in 2022[8] - Net loss totaled $83.9 million for the third quarter of 2023, or $0.87 per share, compared to $14.4 million, or $8.17 per share, for the third quarter of 2022[8] - Total assets were $800.489 million as of September 30, 2023, compared to $319.923 million as of December 31, 2022[6] Clinical Program Updates - Top-line data from the global Phase 2b/3 trial for izokibep in PsA and proof-of-concept data for lonigutamab in thyroid eye disease are expected in the first quarter of 2024[7] - 46-week results from a Phase 2 trial of izokibep in PsA showed >75% achievement of ACR50, >50% achievement of ACR70, >70% achievement of PASI100, >80% resolution of enthesitis, and >50% achievement of Minimal Disease Activity (MDA)[7] - Approximately 25% of patients achieved HiSCR100 responses within 12 weeks in hidradenitis suppurativa trial[7] Leadership and Corporate Updates - Patricia Turney joined as Chief Technical Operations Officer[2] - Shephard (Shep) Mpofu joined as Senior Vice President of Development[7]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to_____. Commission File Number: 001-41696 ACELYRIN, INC. (Exact name of registrant as specified in its charter) Delaware 85-24067 ...

Acelyrin, Inc. (NASDAQ:SLRN) Q2 2023 Earnings Conference Call August 14, 2023 4:30 PM ET Company Participants Tyler Marciniak - VP of Investor Relations, Communications, and Corporate Operations Shao-Lee Lin - Founder and Chief Executive Officer Paul Peloso - Chief Medical Officer Gil Labrucherie - Interim Chief Financial Officer Conference Call Participants Tyler Van Buren - TD Cowen Akash Tewari - Jefferies Vikram Purohit - Morgan Stanley Operator Good afternoon and welcome to the ACELYRIN, INC. Confere ...

Table of Contents x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to_____. Commission File Number: 001-41696 ACELYRIN, INC. (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) Delaware 85-2406735 (S ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to_____. Commission File Number: 001-41696 ACELYRIN, INC. (Exact name of registrant as specified in its charter) Delaware 85-2406735 ( ...